REGENXBIO Inc.
RGNX
$9.01
$0.9011.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.36M | 89.01M | 21.21M | 24.20M | 22.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.36M | 89.01M | 21.21M | 24.20M | 22.30M |
| Cost of Revenue | 5.21M | 56.52M | -151.82M | 66.82M | 10.58M |
| Gross Profit | 16.15M | 32.49M | 173.04M | -42.62M | 11.72M |
| SG&A Expenses | 19.88M | 20.35M | 15.05M | 19.42M | 18.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 45.00K | 15.00K | 833.00K | 37.00K | 29.00K |
| Total Operating Expenses | 84.64M | 76.89M | 72.58M | 86.28M | 78.33M |
| Operating Income | -63.28M | 12.13M | -51.37M | -62.08M | -56.04M |
| Income Before Tax | -70.87M | 6.08M | -51.19M | -59.60M | -52.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.87M | 6.08M | -51.19M | -59.60M | -52.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.87M | 6.08M | -51.19M | -59.60M | -52.99M |
| EBIT | -63.28M | 12.13M | -51.37M | -62.08M | -56.04M |
| EBITDA | -59.37M | 16.08M | -47.35M | -58.12M | -51.99M |
| EPS Basic | -1.38 | 0.12 | -1.01 | -1.17 | -1.05 |
| Normalized Basic EPS | -0.86 | 0.07 | -0.63 | -0.73 | -0.65 |
| EPS Diluted | -1.38 | 0.12 | -1.01 | -1.17 | -1.05 |
| Normalized Diluted EPS | -0.86 | 0.07 | -0.63 | -0.73 | -0.65 |
| Average Basic Shares Outstanding | 51.48M | 51.36M | 50.87M | 50.80M | 50.60M |
| Average Diluted Shares Outstanding | 51.48M | 51.43M | 50.87M | 50.80M | 50.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |